Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2023 08:30 ET | Source: Veru Inc.

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

Reached agreement with FDA on confirmatory Phase 3 clinical trial design in 408 subjects with primary endpoint of all-cause mortality at Day 60 Study to expand treatment population to include all...
April 11, 2023 08:30 ET | Source: Veru Inc.

Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses

Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin for the treatment of poxvirus acute respiratory distress...
December 19, 2022 11:35 ET | Source: The Rosen Law Firm PA

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Veru, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action– VERU

NEW YORK, Dec. 19, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Veru, Inc. (NASDAQ: VERU) between May 11, 2022 and...
November 09, 2022 20:55 ET | Source: Veru Inc.

Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

MIAMI, FL, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...